Although a proposal by the HHS to shift certain prescription drugs from Medicare Part B to Part D may reduce total drug spending by 6.9% to 18.3%, it could also increase out-of-pocket costs for some Medicare beneficiaries, according to a study published in JAMA Internal Medicine.
“The HHS policy blueprint was published on May 11, 2018,” Thomas J. Hwang, AB, of the Program on Regulation, Therapeutics, and Law, division of pharmacoepidemiology and pharmacoeconomics, in the department of medicine at Brigham and Women’s Hospital, Harvard Medical School, and colleagues wrote. “The proposed Medicare Part B reform is an important part of the Trump administration’s strategy to lower drug prices and reduce out-of-pocket costs for Medicare beneficiaries. We modeled the effects of the proposed reform on total drug spending and patients’ out-of-pocket costs for prescription drugs.”
This activity is supported by an independent educational grant from Amarin Pharma Inc.
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.